Novel natural product therapeutics targeting both inflammation and cancer

https://doi.org/10.1016/S1875-5364(17)30062-6Get rights and content

Abstract

Inflammation is recently recognized as one of the hallmarks of human cancer. Chronic inflammatory response plays a critical role in cancer development, progression, metastasis, and resistance to chemotherapy. Conversely, the oncogenic aberrations also generate an inflammatory microenvironment, enabling the development and progression of cancer. The molecular mechanisms of action that are responsible for inflammatory cancer and cancer-associated inflammation are not fully understood due to the complex crosstalk between oncogenic and pro-inflammatory genes. However, molecular mediators that regulate both inflammation and cancer, such as NF-κB and STAT have been considered as promising targets for preventing and treating these diseases. Recent works have further demonstrated an important role of oncogenes (e.g., NFAT1, MDM2) and tumor suppressor genes (e.g., p53) in cancer-related inflammation. Natural products that target these molecular mediators have shown anticancer and anti-inflammatory activities in preclinical and clinical studies. Sesquiterpenoids (STs), a class of novel plant-derived secondary metabolites have attracted great interest in recent years because of their diversity in chemical structures and pharmacological activities. At present, we and other investigators have found that dimeric sesquiterpenoids (DSTs) may exert enhanced activity and binding affinity to molecular targets due to the increased number of alkylating centers and improved conformational flexibility and lipophilicity. Here, we focus our discussion on the activities and mechanisms of action of STs and DSTs in treating inflammation and cancer as well as their structure-activity relationships.

References (135)

  • XR Cheng et al.

    Hookerolides A-D, the first naturally occurring C-17-pseudoguaianolides from Inula hookeri [J]

    Tetrahedron Lett

    (2013)
  • JJ Qin et al.

    New sesquiterpenes from Inula japonica Thunb. with their inhibitory activities against LPS-induced NO production in RAW264.7 macrophages [J]

    Tetrahedron

    (2010)
  • X Cheng et al.

    Sesquiterpene lactones from Inula falconeri, a plant endemic to the Himalayas, as potential anti-inflammatory agents [J]

    Eur J Med Chem

    (2011)
  • XR Cheng et al.

    Bioactive eudesmane and germacrane derivatives from Inula wissmanniana Hand.-Mazz [J]

    Phytochemistry

    (2013)
  • JJ Qin et al.

    Selective cytotoxicity, inhibition of cell cycle progression, and induction of apoptosis in human breast cancer cells by sesquiterpenoids from Inula lineariifolia Turcz [J]

    Eur J Med Chem

    (2013)
  • JJ Qin et al.

    Japonicones A-D, bioactive dimeric sesquiterpenes from Inula japonica Thunb [J]

    Bioorg Med Chem Lett

    (2009)
  • JX Zhu et al.

    Japonicones Q-T, four new dimeric sesquiterpene lactones from Inula japonica Thunb. [J]

    Fitoterapia

    (2013)
  • Z Hu et al.

    Japonicone A antagonizes the activity of TNF-alpha by directly targeting this cytokine and selectively disrupting its interaction with TNF receptor-1 [J]

    Biochem Pharmacol

    (2012)
  • LY Kong et al.

    Artemisinin, a miracle of traditional Chinese medicine [J]

    Nat Prod Rep

    (2015)
  • KS Wang et al.

    Artemisinin inhibits inflammatory response via regulating NF-kappaB and MAPK signaling pathways [J]

    Immunopharmacol Immunotoxicol

    (2016)
  • AE Mercer et al.

    The role of heme and the mitochondrion in the chemical and molecular mechanisms of mammalian cell death induced by the artemisinin antimalarials [J]

    J Biol Chem

    (2011)
  • I Nakase et al.

    Transferrin receptor-dependent cytotoxicity of artemisinin-transferrin conjugates on prostate cancer cells and induction of apoptosis [J]

    Cancer Lett

    (2009)
  • X Li et al.

    Preclinical efficacy and safety assessment of artemisinin-chemotherapeutic agent conjugates for ovarian cancer [J]

    EBioMedicine

    (2016)
  • S Shalapour et al.

    Immunity, inflammation, and cancer: an eternal fight between good and evil [J]

    J Clin Invest

    (2015)
  • SM Crusz et al.

    Inflammation and cancer: advances and new agents [J]

    Nat Rev Clin Oncol

    (2015)
  • EZ Chai et al.

    Analysis of the intricate relationship between chronic inflammation and cancer [J]

    Biochem J

    (2015)
  • JV Fernandes et al.

    The role of the mediators of inflammation in cancer development [J]

    Pathol Oncol Res

    (2015)
  • DB Vendramini-Costa et al.

    Molecular link mechanisms between inflammation and cancer [J]

    Curr Pharm Des

    (2012)
  • M Baniyash et al.

    Chronic inflammation and cancer: suppressing the suppressors [J]

    Cancer Immunol Immunother

    (2014)
  • JA DiDonato et al.

    NF-kappaB and the link between inflammation and cancer [J]

    Immunol Rev

    (2012)
  • Y Fan et al.

    NF-kappaB and STAT3 signaling pathways collaboratively link inflammation to cancer [J]

    Protein Cell

    (2013)
  • MG Pan et al.

    NFAT gene family in inflammation and cancer [J]

    Curr Mol Med

    (2013)
  • K Balamurugan

    HIF-1 at the crossroads of hypoxia, inflammation, and cancer [J]

    Int J Cancer

    (2016)
  • S Nag et al.

    The MDM2-p53 pathway revisited [J]

    J Biomed Res

    (2013)
  • JJ Qin et al.

    Natural product MDM2 inhibitors: anticancer activity and mechanisms of action [J]

    Curr Med Chem

    (2012)
  • B Zhang et al.

    Small-molecule MDM2- p53 inhibitors: recent advances [J]

    Future Med Chem

    (2015)
  • PC Lv et al.

    Recent advances of p53-MDM2 small molecule inhibitors (2011-present) [J]

    Curr Med Chem

    (2015)
  • M Ebrahim et al.

    MDM2 beyond cancer: podoptosis, development, inflammation, and tissue regeneration [J]

    Histol Histopathol

    (2015)
  • C Ihling et al.

    Co-expression of p53 and MDM2 in human atherosclerosis: implications for the regulation of cellularity of atherosclerotic lesions [J]

    J Pathol

    (1998)
  • JM Coindre et al.

    Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity [J]

    J Pathol

    (2004)
  • JE Goodman et al.

    Nitric oxide and p53 in cancer-prone chronic inflammation and oxyradical overload disease [J]

    Environ Mol Mutagen

    (2004)
  • T Hashimoto et al.

    Inhibition of MDM2 attenuates neointimal hyperplasia via suppression of vascular proliferation and inflammation [J]

    Cardiovasc Res

    (2011)
  • R Ravi et al.

    p53-mediated repression of nuclear factor-kappaB RelA via the transcriptional integrator p300 [J]

    Cancer Res

    (1998)
  • GA Webster et al.

    Transcriptional cross talk between NF-kappaB and p53 [J]

    Mol Cell Biol

    (1999)
  • A Dey et al.

    Nutlin-3 inhibits the NFkappaB pathway in a p53-dependent manner: implications in lung cancer therapy [J]

    Cell Cycle

    (2007)
  • W Zhiyu et al.

    The inflammasome: an emerging therapeutic oncotarget for cancer prevention [J]

    Oncotarget

    (2016)
  • M Saxena et al.

    NOD-like receptors: Master regulators of inflammation and cancer [J]

    Front Immunol

    (2014)
  • ST Liu et al.

    Src as the link between inflammation and cancer [J]

    Front Physiol

    (2013)
  • S Safe et al.

    Natural products as mechanism-based anticancer agents: Sp transcription factors as targets [J]

    Phytother Res

    (2016)
  • DJ Newman et al.

    Natural products as sources of new drugs from 1981 to 2014 [J]

    J Nat Prod

    (2016)
  • Cited by (50)

    View all citing articles on Scopus

    Available online 20 Jun., 2017

    [Research funding] This work was supported by NIH/NCI (Grant R01 CA186662 to R.Z.) and by American Cancer Society (Grant RSG-15-009-01-CDD to W.W.).

    These authors have no conflict of interest to declare.

    View full text